Supreme Court Upholds Medicare Price Negotiations as Novo Nordisk Slashes Blockbuster Prices by 50%

A dual wave of legal and corporate pricing shifts has fundamentally restructured the U.S. GLP-1 market. On May 18, 2026, the U.S. Supreme Court rejected a series of appeals from major pharmaceutical manufacturers, leaving in place federal appeals court rulings that upheld the Medicare Drug Price Negotiation program established under the 2022 Inflation Reduction Act (IRA).

Supreme Court Ruling and the Legal Context

The Supreme Court's refusal to hear the challenges represents a definitive victory for the federal government's drug-pricing agenda:

• Precedent Upheld: The high court left in place a ruling from the Third Circuit Court of Appeals in Philadelphia that dismissed drugmaker claims that the negotiation program was unconstitutional.
• Broad Scope: The negotiation program, which has faced fierce opposition from the pharmaceutical industry, has already targeted 25 high-cost drugs. In January 2026, the Trump administration announced a third round of targeted drugs, which will expand the program's reach to 40 total therapies.
• No End Date: Because the enabling statute does not contain an expiration date, stopping the program would now require a direct act of Congress.

Semaglutide Medicare Pricing (IPAY 2027)

Novo Nordisk's blockbuster semaglutide products—Ozempic, Rybelsus, and Wegovy—were selected in January 2025 during the second round of negotiations (representing the Initial Price Applicability Year or IPAY 2027). Under CMS Administrator Mehmet Oz, the negotiated Maximum Fair Prices (MFPs) were officially unveiled on November 25, 2025:

• Negotiated Price: The Medicare negotiated price for semaglutide was set at $274 per month, scheduled to take effect on January 1, 2027.
• Budget Impact: This negotiated price represents a massive discount compared to historical Medicare spending on these drugs, which has cost the federal government billions of dollars annually.

Novo Nordisk's Strategic Response: 50% List Price Cuts

Coinciding with the upcoming implementation of the Medicare negotiated prices, Novo Nordisk executed a defensive, market-wide pricing maneuver on February 24, 2026. The Danish drugmaker announced it will cut the U.S. list prices of its blockbuster semaglutide portfolio by up to 50%, effective January 1, 2027:

• New Flat Rate: Both Ozempic and Wegovy (including the Wegovy pill and Rybelsus) will have their U.S. list prices set at $675 per month.
• Magnitude of Cuts: This represents a 50% reduction for Wegovy (down from its launch list price of $1,349 per month) and a 34% to 35% reduction for Ozempic (down from $997 per month).
• Strategic Rationale: Jamey Millar, Novo's Executive Vice President of U.S. Operations, stated that the cuts are designed to lower out-of-pocket exposure for patients in the commercial market whose co-insurance or high-deductible health plans are directly tied to the list price.
• PBM and Formulary Protection: Industry analysts note that by lowering list prices, Novo Nordisk aims to maintain broad commercial formulary access and defend its market share against emerging oral and injectable competitors as the cash-pay and high-deductible patient channels become increasingly price-sensitive.